Press Release History
2011 | 2010 | 2009 | 2008 | 2007
2011
December 23, 2011
ThromboGenics Submits Biologics License Application for Ocriplasmin to the U.S. FDA… More
December 16, 2011
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule … more »
November 24, 2011
ThromboGenics Appoints Thomas Clay as New Board Member… more »
November 3, 2011
ThromboGenics NV - business update… more »
October 20, 2011
ThromboGenics Announces Dr Julia Haller to Present Ocriplasmin Phase III Responder Analysis at Opening Session of AAO (American Academy of Ophthalmology) Retina Subspecialty Day … more »
October 19, 2011
ThromboGenics Announces EMA Acceptance for Review of Marketing Authorisation Application for Ocriplasmin … more »
August 24, 2011
ThromboGenics Business Update and financial results … more »
August 22, 2011
ThromboGenics Announces New Phase III Ocriplasmin Data … more »
August 9, 2011
ThromboGenics on Track to File Ocriplasmin by End of 2011… more »
June 7, 2011
ThromboGenics to Present at the Jefferies 2011 Global Life Sciences Conference in New York… more »
May 16, 2011
ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche… more »
May 12, 2011
ThromboGenics NV - business update… more »
April 27, 2011
ThromboGenics and BioInvent have dosed the first patient in Phase IIb trial of TB-402 (Anti-factor VIII) for venous thromboembolism (VTE) prophylaxis… more »
April 1, 2011
ThromboGenics increases share capital through warrant exercises… more »
March 10, 2011
ThromboGenics announces business update and 2010 full-year results … more »
February 11, 2011
Positive TB-402 Phase II data published in Journal of Thrombosis and Haemostasis… more »
February 4, 2011
Clot-busting drug THR-100 (staphylokinase) enters Phase III clinical trials in India… more »
January 20, 2011
ThromboGenics presents positive pooled results from the MIVI-TRUST Phase III program… more »
2010
December 3, 2010
ThromboGenics successfully completes private placement raising €56 million… more ⇒
December 2, 2010
ThromboGenics announces a private placement of new ordinary shares… more ⇒
November 5, 2010
Transparency notification… more ⇒
November 5, 2010
ThromboGenics NV - business update… more ⇒
October 29, 2010
ThromboGenics receives transparency notification… more ⇒
October 26, 2010
ThromboGenics raises €2.8 miillion from the exercise of warrants… more ⇒
September 30, 2010
ThromboGenics signs deal with MSD for long-term commercial supply for microplasmin… more ⇒
September 15, 2010
ThromboGenics NV – transparency declaration… more ⇒
September 14, 2010
Transparency information… more ⇒
September 6, 2010
ThromboGenics presents positive pooled results from the MIVI-TRUST Phase III program, confirming microplasmin’s potential to transform the treatment of retinal disorders… more ⇒
September 1, 2010
Microplasmin meets primary end point in second Phase III trial in VMA, confirms positive findings of first trial… more ⇒
August 26, 2010
ThromboGenics NV announces 2010 first half results … more ⇒
July 15, 2010
ThromboGenics announces publication of positive microplasmin Phase II data in the journal Retina… more ⇒
July 9, 2010
Positive results from Phase II VTE prophylaxis study with TB-402 (anti-factor VIII) presented at the 21st International Congress on Thrombosis in Milan, Italy… more ⇒
July 1, 2010
ThromboGenics to present results of second Phase III trial of microplasmin at the 28th Annual Meeting of the American Society of Retina Specialists (ASRS) and the 10th EURETINA Congress… more ⇒
June 7, 2010
ThromboGenics presents new exciting microplasmin Phase III data at the World Ophthalmology Congress in Berlin… more ⇒
June 4, 2010
ThromboGenics to present at the Jefferies 2010 Global Life Sciences Conference in New York on June 10… more ⇒
May 17, 2010
ThromboGenics and BioInvent to receive €10 million milestone as partner Roche begins new clinical study with TB-403… more ⇒
May 11, 2010
ThromboGenics’ business update… more ⇒
May 6, 2010
ThromboGenics and BioInvent announce positive topline results from Phase II VTE Prophylaxis study with anti-factor VIII… more ⇒
April 20, 2010
ThromboGenics announces that microplasmin meets primary end point in Phase III trial… more ⇒
March 25, 2010
ThromboGenics raises €0.6 million from the exercise of warrants… more ⇒
March 12, 2010
ThromboGenics announces business update and 2009 full year results… more ⇒
February 9, 2010
ThromboGenics – Positive microplasmin Phase II data published in Ophthalmology… more ⇒
2009
December 16, 2009
ThromboGenics completes patient enrollment of second Phase III trial of microplasmin for the non-surgical treatment of eye disease… more »
December 11, 2009
ThromboGenics announces start of Phase II trial of microplasmin for the treatment of age-related macular degeneration (AMD)… more »
November 18, 2009
ThromboGenics and BioInvent win “Licensing Deal of the Year” at the Scrip Awards 2009… more »
November 16, 2009
ThromboGenics and BioInvent complete Phase I patient trial of anti-PlGF cancer therapeutic TB-403… more »
AACR-NCI-EORTC Conference healthy volunteer results poster – AACR-NCI-EORTC Conference cancer patients results poster
November 4, 2009
ThromboGenics is today issuing a business update for the 9-month period ended 30 September 2009… more »
October 28, 2009
ThromboGenics and BioInvent complete patient recruitment of Phase II DVT prophylaxis study with anti-factor VIII (TB-402)… more »
October 9, 2009
ThromboGenics raises €0.6 million from the exercise of warrants… more »
October 5, 2009
ThromboGenics announces results from a Phase IIa trial evaluating microplasmin for the treatment of diabetic macular edema… more »
September 24, 2009
ThromboGenics completes patient enrollment in US Phase III trial of microplasmin for the non-surgical treatment of eye disease… more »
September 11, 2009
ThromboGenics is shortlisted for “Biotech Company of the Year” and “Licensing Deal of the Year” at Scrip Awards 2009… more »
August 27, 2009
ThromboGenics NV announces business update and half-year results 2009… more »
July 3, 2009
ThromboGenics and BioInvent start recruitment of second 100-patient cohort in Phase II study… more »
June 30, 2009
ThromboGenics promoted to the NEXT 150 Index… more »
June 25, 2009
ThromboGenics’ microplasmin Phase III program progressing according to schedule… more »
May 14, 2009
ThromboGenics is today issuing a business update for the 3-month period ended 31 March 2009… more »
May 7, 2009
ThromboGenics raises €3.1 million from the exercise of warrants… more »
March 12, 2009
ThromboGenics announces business update and 2008 full year results…more »
March 6, 2009
ThromboGenics completes patient enrollment for Phase II trial of microplasmin for the treatment of diabetic macular edema… more »
February 27, 2009
ThromboGenics awarded €3.2 million grant for the development of its anti-VPAC1 antibody for cancer chemotherapy induced thrombocytopenia… more »
February 23, 2009
ThromboGenics and BioInvent start Phase II trial of TB-402, a novel, long-acting anticoagulant for deep vein thrombosis (DVT) prophylaxis… more »
January 31, 2009
ThromboGenics’ proprietary cell lines introduced by GenOway in new stem cell production technology… more »
January 26, 2009
ThromboGenics and BioInvent receive technology transfer success fee from Roche for the novel anti-cancer antibody, TB-403 (Anti-PlGF)… more »
January 9, 2009
ThromboGenics begins Phase III program with microplasmin for the non-surgical treatment of back-of-the-eye disease … more »
2008
August 28, 2008
ThromboGenics announces half-year results 2008… more »
March 13, 2008
ThromboGenics announces 2007 full-year results… more »
2007
August 24, 2007
ThromboGenics announces interim results… more »
February 15, 2007
ThromboGenics announces business update and half-year results… more »